Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer

Advances in Therapy

Volumn 26, Issue SUPPL.1, 2009, Pages

  Fiúza, Manuela ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Breast cancer; Cardiotoxicity; HER2+; Trastuzumab

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIAC GLYCOSIDE; CYCLOPHOSPHAMIDE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOTROPIC AGENT; NITRATE; PACLITAXEL; TRASTUZUMAB; TROPONIN I;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIASTOLIC DYSFUNCTION; EARLY DIAGNOSIS; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC DYSFUNCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RISK FACTORS; STROKE VOLUME; TROPONIN I;

EID: 74049100179     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0048-z     Document Type: Review

References (36)

1. M.J. Piccart-Gebhart M. Procter B. Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
2. D.L. Keefe 2002 Trastuzumab-associated cardiotoxicity Cancer 95 1592 1600 12237930 10.1002/cncr.10854 1:CAS:528:DC%2BD38XnvV2qur8%3D
3. A. Goldhirsch W.C. Wood R.D. Gelber, et al. 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
4. D.J. Slamon G.M. Clark S.G. Wong W.J. Levin A. Ullrich W.L. McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
5. C.A. Hudis 2007 Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 39 51 17611206 10.1056/NEJMra043186 1:CAS:528:DC%2BD2sXnsVygu7s%3D (Pubitemid 47026733)
6. M.A. Cobleigh C.L. Vogel D. Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 10561337 1:CAS:528:DyaK1MXmtlWrurk%3D
7. D.J. Slamon B. Leyland-Jones S. Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
8. M. Marty F. Cognetti D. Maraninchi, et al. 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D (Pubitemid 46207001)
9. A. Lin H.S. Rugo 2007 The role of trastuzumab in early stage breast cancer: current data and treatment recommendations Curr Treat Options Oncol 8 47 60 17660958 10.1007/s11864-007-0008-2
10. V. Guarneri D.J. Lenihan V. Valero, et al. 2006 Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience J Clin Oncol 24 4107 4115 16908934 10.1200/JCO.2005.04.9551 1:CAS:528:DC%2BD28XhtVantb3F (Pubitemid 46622286)
11. M.L. Telli S.A. Hunt R.W. Carlson A.E. Guardino 2007 Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 3525 3533 17687157 10.1200/JCO.2007.11.0106 1:CAS:528:DC%2BD2sXhtVajsb3M (Pubitemid 47310891)
12. E.A. Perez V.J. Suman N.E. Davidson, et al. 2008 Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial J Clin Oncol 26 1231 1238 18250349 10.1200/JCO.2007.13.5467 1:CAS:528:DC%2BD1cXksVehu7s%3D
13. I. Smith M. Procter R.D. Gelber, et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
14. H. Joensuu P.L. Kellokumpu-Lehtinen P. Bono, et al. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 16495393 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
15. M.S. Ewer D.J. Lenihan 2008 Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 26 1201 1203 18227525 10.1200/JCO.2007.14.8742
16. P.K. Singal N. Iliskovic 1998 Doxorubicin-induced cardiomyopathy N Engl J Med 339 900 905 9744975 10.1056/NEJM199809243391307 1:STN:280:DyaK1cvhsVektw%3D%3D (Pubitemid 28446849)
17. K. Chien 2006 Herceptin and the heart-a molecular modifier of cardiac failure N Engl J Med 354 789 790 16495390 10.1056/NEJMp058315 1:CAS:528:DC%2BD28XhslOmsb4%3D (Pubitemid 43290916)
18. M.S. Ewer S.M. Lippman 2005 Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2900 2902 15860848 10.1200/JCO.2005.05.827 1:CAS:528:DC%2BD2MXkslGhurg%3D (Pubitemid 46224107)
19. D.F. Hayes 2006 Heart of darkness: the downside of trastuzumab J Clin Oncol 26 4056 4058 10.1200/JCO.2006.07.5143 (Pubitemid 46622279)
20. J.A. Sparano 2001 Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials Semin Oncol 28 20 27 11301371 10.1016/S0093-7754(01)90189-7 1:CAS:528:DC%2BD3MXjtFWqsr0%3D
21. T.F. Chu M.A. Rupnick R. Kerkela, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2011 2019 18083403 10.1016/S0140-6736(07)61865-0 1:CAS:528:DC%2BD2sXhsVent7bN (Pubitemid 350236338)
22. E.A. Perez R. Rodeheffer 2004 Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 322 329 14722042 10.1200/JCO.2004.01.120 1:CAS:528:DC%2BD2cXpsVKitLY%3D (Pubitemid 41095098)
23. T.M. Suter N. Cook-Bruns C. Barton 2004 Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer Breast 13 173 183 15177418 10.1016/j.breast.2003.09.002 1:STN:280:DC%2BD2c3nsl2gtw%3D%3D (Pubitemid 38937119)
24. A. Seidman C. Hudis M.K. Pierri, et al. 2002 Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215 1221 11870163 10.1200/JCO.20.5.1215 1:CAS:528:DC%2BD38XisVWmuro%3D (Pubitemid 34177427)
25. Harvey RM, Doyle EF, Ellis K, et al. The Criteria Committee of the New York Heart Associaton (NYHA). Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th edition. Boston, MA: Little, Brown and Co. 1994:253-256.
26. P. Rastogi J. Jeong C.E. Geyer, et al. 2007 Five year up-date of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H) J Clin Oncol 25 suppl.18s LBA513
27. D. Cardinale M. Sandri A. Colombo, et al. 2004 Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2749 2754 15148277 10.1161/01.CIR.0000130926.51766.CC 1:CAS:528:DC%2BD2cXksVKgtbw%3D (Pubitemid 38737923)
28. D. Cardinale M.T. Sandri A. Martinani, et al. 2002 Myocardial injury revealed by plasma troponin I in breast cancer treated with high dose chemotherapy Ann Oncol 13 710 715 12075738 10.1093/annonc/mdf170 1:STN:280:DC%2BD38zjtlWrsA%3D%3D (Pubitemid 34567376)
29. J.A. Sparano D.L. Brown C. Wolff 2002 Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers Drug Saf 25 301 311 12020170 10.2165/00002018-200225050-00001 1:CAS:528:DC%2BD38Xlt1Khtr4%3D
30. D. Cardinale A. Colombo M.T. Sandri, et al. 2006 Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2474 2481 17101852 10.1161/CIRCULATIONAHA.106.635144 1:CAS:528:DC%2BD28Xht1CqurzI (Pubitemid 44901520)
31. H.W. Auner C. Tinchon W. Linkesch, et al. 2003 Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies Ann Hematol 82 218 222 12679885 1:CAS:528:DC%2BD3sXjtVeiu7k%3D
32. E.H. Herman J. Zhang S.E. Lipshultz, et al. 1999 Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin J Clin Oncol 17 2237 2243 10561281 1:CAS:528:DyaK1MXkvVSmu78%3D
33. Heart Failure Society of America. 2006 Executive summary. FSA 2006 comprehensive heart failure practice guidelines J Card Fail 12 10 38 10.1016/j.cardfail.2005.12.001 (Pubitemid 43267749)
34. L.W. Jones M.J. Haikowsky J.J. Swartz, et al. 2007 Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 50 1435 1441 17919562 10.1016/j.jacc.2007.06.037 (Pubitemid 47494586)
35. M.S. Ewer M.T. Vooletich J.B. Durand, et al. 2005 Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820 7826 16258084 10.1200/JCO.2005.13.300 1:CAS:528:DC%2BD2MXht1Cqs7bP (Pubitemid 46657379)
36. P.P. Sengupta D.W. Northfelt F. Gentile J.L. Zamorano B.K. Khandheria 2008 Trastuzumab-induced cardiotoxicity: heart failure at the crossroads Mayo Clin Proc 83 197 203 18241629 10.4065/83.2.197 1:CAS:528:DC%2BD1cXisFCqt7o%3D (Pubitemid 351303103)